Aytu BioScience is trading 5.47% higher at $2.12 on October 21, 2026, with biotech-sector strength a possible context for the move. - Biotech ETF XBI is up 2.10%, amid biotech M&A activity and positive clinical-trial news; this does not establish the precise cause of Aytu’s intraday move. - Search results showed no company-specific announcement or other clear Aytu catalyst; the company’s latest listed press releases were from September.